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Accepted 19 November 2018; Published online 28 November 2018AbstractObjectives: The Consolidated Standards of Reporting Trials extension for the stepped-wedge cluster randomized trial (SW-CRT) is a
recently published reporting guideline for SW-CRTs. We assess the quality of reporting of a recent sample of SW-CRTs.
Study Design and Setting: Quality of reporting was asssessed according to the 26 items in the new guideline using a novel crowd
sourcing methodology conducted independently and in duplicate, with random assignment, by 50 reviewers. We assessed reliability of
the quality assessments, proposing this as a novel way to assess robustness of items in reporting guidelines.
Results: Several items were well reported. Some items were very poorly reported, including several items that have unique require-
ments for the SW-CRT, such as the rationale for use of the design, description of the design, identification and recruitment of participants
within clusters, and concealment of cluster allocation (not reported in more than 50% of the reports). Agreement across items was moderate
(median percentage agreement was 76% [IQR 64 to 86]). Agreement was low for several items including the description of the trial design
and why trial ended or stopped for example.
Conclusions: When reporting SW-CRTs, authors should pay particular attention to ensure clear reporting on the exact format of the
design with justification, as well as how clusters and individuals were identified for inclusion in the study, and whether this was done before
or after randomization of the clusters, which are crucial for risk of bias assessments. Some items, including why the trial ended, might either
not be relevant to SW-CRTs or might be unclearly described in the statement.  2018 Elsevier Inc. All rights reserved.
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The stepped-wedge cluster randomized trial (SW-CRT)
is a novel cluster randomized trial design that is particularly
valuable in implementation research and becoming more
commonly used [1-3]. It is particularly relevant for evalu-
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0895-4356/ 2018 Elsevier Inc. All rights reserved.organizations [4]. The SW-CRT involves randomization
of clusters (e.g., primary care units, wards, hospitals) to
different sequences that dictate the order in which each
cluster will switch to the intervention condition [5]. The
CONSORT (Consolidated Standards of Reporting Trials)
statement, which outlines key characteristics to be reported
in a parallel arm individually randomized trial [6], has
recently been extended to provide a reporting guideline
specific to SW-CRTs (referred to as the CONSORT exten-
sion for the SW-CRT) [7]. Although the earlier CONSORT
extension for cluster randomized trials provides reporting
guidance for trials in which groups of individuals (clusters)
are randomized [8], there are many differences between the
SW-CRT and the parallel cluster trial.
Key design characteristic of the SW-CRT (which do not
typically feature in a parallel CRT conducted at a single
inical Epidemiology 107 (2019) 77e88What is new?
Key findings
 How the design, results and interpretation of a SW-
CRT should be reported is different to that of indi-
vidually randomised and parallel cluster trials.
 Quality of reporting can been assessed using
crowd-sourcing.
What this adds to what was known?
 Whilst this review echoes the findings of many
other assessments of reporting reviews, that report-
ing needs to be improved, we provide clear guid-
ance on specific components that are frequently
poorly reported.
 Any future updates of the CONSORT extension for
SW-CRTs should pay careful attention to the
wording and relevance reporting why the trial
stopped and how the intervention was blinded,
which may not be relevant to many SW-CRTs.
What is the implication and what should change
now?
 When reporting SW-CRTs authors should ensure
clear reporting on the exact format of the design
with justification, as well as how clusters and indi-
viduals were identified for inclusion in the study,
and whether this was done before or after random-
isation of the clusters.
cross section) includes whether the design repeatedly mea-
sures the same individuals [9]; whether the study is de-
signed with an equal number of clusters allocated to each
sequence; whether the study incorporates a transition
period (a time period in which the intervention is embedded
into practice) [4]; whether participants are recruited into the
study before randomization; whether cross-sectional sam-
ples are selected for outcome assessment; and whether out-
comes are ascertained for a complete enumeration of the
cluster members using routinely collected data. Further-
more, the design is also susceptible to several risks of
biases particular to the SW-CRT, including confounding
with time [10,11], complex within-cluster correlation pat-
terns [12-15], the risk of within-cluster contamination
[9,7], the possibility of time varying treatment effects
[16,10,11], and risks of recruitment or selection biases
[7,17].
Several systematic reviews have examined the quality of
reporting of SW-CRTs. These have reported lack of clarity
of the design, reporting of time adjustments, and key ethical
aspects such as consent and ethical oversight [1,18,2,3,19].
Although only about 40 completed SW-CRTs have been
78 K. Hemming et al. / Journal of Clidentified by these reviews, there has been an exponential in-
crease in the use of this design over the past few years with an
expected further increase in the near future.
Here we report the results of a systematic review of an
assessment of the quality of reporting of a recent sample
of SW-CRTs according to the newly developed reporting
guideline. The aims of this review were to determine the
quality of reporting of a recent set of SW-CRTs according
to this newly developed guideline, to flag areas that are
particularly poorly reported (to encourage immediate
improved reporting), and to provide a baseline assessment
for future studies examining any changes over time. This
assessment of quality of reporting was conducted by 50 re-
viewers, with random assignment, so that each assessment
of quality of reporting was performed independently by two
reviewers. This was followed by a discussion to resolve dif-
ferences, leading to a joint assessment. Although not a pri-
mary aim, we also assessed the reliability of the
independent assessments. Measures of reliability of the in-
dependent assessments were used to suggest potential items
in the statement where the wording might be unclear.2. Methods
We identified a sample of recently publishedSW-CRT trials,
whichwere then randomly allocated to 50 reviewers for quality
assessment.Wecapitalizedon thewillingness, interest, and skill
set of participants (the reviewers) attending a workshop on the
reporting of SW-CRTs inLondon,UK, duringNovember 2017.
To allow for independent extraction by two reviewers per trial
report and to allow for the possibility of more participants
attending the workshop than expected, we sought to identify
approximately 30 SW-CRT trial reports. Specific objectives
were to assess agreement between reviewers and to provide a
joint assessment of the quality of reporting according to the
new CONSORT extension for this trial design.2.1. Scope of this review
We included SW-CRTs with a minimum of three se-
quences (where a sequence is defined as a unique allocation
of periods spent in the control condition followed by pe-
riods in the intervention condition). One exception made
to these criteria was to include trials with two sequences
and three periods, which are also considered SW-CRTs
by the new reporting guideline. We included only studies
comparing two treatment conditions. We did not restrict in-
clusion to those designs with all clusters initiating in the
control condition and ending up in the intervention condi-
tion. Only studies using the cluster as the unit of randomi-
zation were included. We included only primary reports of
SW-CRTs; protocols and reports of secondary analyses of a
previously reported trial were excluded. Reports had to be
open access or viewable from either the University of Bir-
mingham or University of Ottawa libraries and had to be
79K. Hemming et al. / Journal of Clinical Epidemiology 107 (2019) 77e88published in English. Focusing on the most recently pub-
lished trials helped ensure that our assessment of reporting
quality was current and avoided any overlap with earlier
systematic reviews of SW-CRTs. A protocol for the review
was not registered with PROSPERO (a database of proto-
cols for systematic reviews) as it was out of remit.2.2. Search strategy
We identified eligible studies in MEDLINE (accessed us-
ing PubMed) using a previously published electronic search
strategy ([2]; Table S1) run on the November 21, 2017
(including variations of the search terms ‘‘stepped wedge’’,
‘‘experimentally stated introduction’’, ‘‘delayed interven-
tion’’). We identified and ordered studies in descending order
by date listed in MEDLINE. To allow for exclusion of ineli-
gible studies, titles and abstracts of the first 50 studies were
identified. The title and abstracts of these 50 studies were
screened independently by two authors (K.H. and M.T.).
Any differences were resolved by discussion. Those studies
not meeting the eligibility criteria were excluded. For the re-
maining studies, full copies of the trial reports were then ob-
tained and assessed against the inclusion criteria.2.3. Data abstraction process
Data abstraction was undertaken by delegates attending
a workshop in London on the reporting of SW-CRTs on
November 30, 2017. The workshop was run as a part of
an annual methodological meeting (including workshops
and short invited and contributed talks) on current develop-
ments in cluster randomized and stepped-wedge trials. The
workshop was a low cost (£50) event with open attendance,
but for which preregistration was necessary.
In preparation for the event, we invited all registered del-
egates to participate in the review. Participants were
informed that attending the workshop would require under-
taking a small amount of work in advance and during the
event, with an invitation to contribute to the resulting article
as a group author. Anyone not wishing to participate in the
process was invited to opt out (by 24 November), and any
collected data would be excluded should the participant so
wish. Participants were also informed that data on inter-
rater reliability as well as the quality of reporting would
be anonymously evaluated. Participants were free to not
participate in this activity while still attending the meeting.
Participants not opting out were randomly allocated to
one of the trial reports using computer-generated numbers,
so that two participants were allocated to each study. One
week in advance of the meeting, a full PDF copy of their
allocated study was e-mailed to each participant. Partici-
pants were asked to independently assess the quality of re-
porting according to the 26 items in the newly proposed
CONSORT extension for SW-CRTs (using a simple tool
provided Appendix 1). Participants were kept blind to the
other allocated assessor of the same report until themorning of the workshop. Participants were requested to
bring a hard copy of the completed quality of reporting
assessment tool with them to the workshop.
At the beginning of the workshop, participants listened
to a 30-minute presentation (by K.H. and M.T.) summari-
zing the most salient points of the new reporting guideline.
After this, the two participants assigned to each trial report
met for a 30-minute period, discussed any discrepancies,
and reached a consensus for each of the 26 quality assess-
ment items (hereafter called the joint assessment). Two fa-
cilitators (K.H. and M.T.) provided advice on any issues of
clarity. At the end of the workshop, participants submitted
their completed independent assessments (which they were
asked not to change during the joint assessment process)
and joint assessments. Data were therefore abstracted inde-
pendently and in duplicate for each trial report.2.4. Data abstracted
For each item, participant reviewers were provided with
the wording of the checklist item and asked to assess
whether the item was reported in their assigned study
(Appendix 1). Reviewers were asked to assess the quality
of reporting for each of the 26 items according to a four-
point scale (clearly reported in full/clearly but partially re-
ported/unclearly reported/not reported). However, feed-
back from reviewers following the independent
assessment indicated the need for a ‘‘not applicable’’
response in the scale. As a consequence, the response scale
was changed to a five-point scale with the addition of ‘‘not
applicable’’ for the joint assessment. All reviewers
completing the joint assessment were made aware of this
change of scale. Some independent assessments also inde-
pendently decided to add a ‘‘not applicable’’ option,
whereas others did not. Several of the 26 items have two
or three subitems, leading to a total of 40 items undergoing
assessment. These data were abstracted and entered into an
Excel database by one person (K.H.).2.5. Statistical analysis
First, we described for each item, the reliability of the
quality assessment using percentage agreement (within
item across pairs) and the Gwet A1 statistic (Gwet 2013)
using the kappaetc command in Stata 14, chosen because
the study design was of reviewers nested within articles.
Percentage agreements were compared using the four-
point scale and by dichotomizing the four-point scale into
a two-point scale (clearly reported including clearly re-
ported in full or clearly but partially reported vs. not clearly
reported, which includes unclearly reported or not re-
ported). Independent reviews were excluded from the as-
sessments of reliability if only one of the pair submitted
their independent assessments (n5 3). Any individual level
items, which were missing in either one or both indepen-
dent assessments, were also excluded (numbers included
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Fig. 1. Flow diagram of studies included in the review.
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cable because this was not included in the independent
assessment tool. Items with low agreement might be
considered to be items that are less clearly described in
the statement than those with higher agreement.
We then described the joint assessment based on the
consensus achieved between the reviewer pairs of reporting
quality for all 26 items, along with the average number of
items clearly reported for each report (or assessed as not
applicable). Here, items assessed as not applicable were
counted as clearly reported as all reviewers were aware
of the inclusion of the category not applicable at the joint
assessment stage and because this was deemed the best
way not to penalize the assessment of quality of reporting
when items were deemed not applicable. Any item assess-
ments missing from the joint assessments were excluded
(10 out of a total of 1,000 possible assessments).
Finally, for completeness we describe for each paper
and each pair of reviewers the percentage agreement
across items (within pair across items) and the corre-
sponding measure of reliability (again excluding any as-
sessments of not applicable, missing independent
assessments, and missing individual item assessments).
Reviewer pairs with very low (or very high) agreement
might indicate reviewers with low (or high) expertise or
articles that are clearly (or unclearly) reported. Alongside
this, we report the joint assessment of quality of reporting
for each study.3. Results
3.1. Identified studies
The initial search identified 437 potential articles for in-
clusion (Fig. 1). The most recently published 50 of these
were screened in duplicate. Of these 50 studies, seven were
excluded because they were not randomized; seven were
excluded because they were protocols and not full reports;
four were excluded because they were individually random-
ized; three were excluded because they reported a second-
ary analysis; one was excluded because it was a methods
paper; and an additional two were excluded because they
were not accessible. Of these exclusions, two were
excluded in the full paper screen (one secondary analysis;
and one because it did not clearly randomize clusters);
and the others were excluded on the abstract screen. This
therefore meant a total of 24 studies were excluded, leaving
26 for inclusion. One study was later identified as not
meeting the inclusion criteria by a reviewer and was also
excluded (individually randomized), leaving 25 trial reports
for inclusion in the analysis. A description of the 25 studies
is provided in Table 1.
3.2. Participant reviewers
A total of 53 participants registered for the workshop
(Fig. 2). Of these, three participants (A.F., J.T., and group
author J.M. who were all participants of the Delphi group
Table 1. Characteristics of the included stepped-wedge cluster
randomized trial study reports
Characteristic
Frequency (%)
N [ 25 reports in total
Publication year
2017 13 (52%)
2016 12 (48%)
Journal impact factor
Median (IQR) 2.8 (2.1e9.8)
Country of study
High income country
UK or Ireland 5 (20%)
Netherlands 5 (20%)
Canada or US 3 (12%)
Australia 2 (8%)
Other 3 (12%)
Low-income country 5 (20%)
Middle-income country 1 (4%)
Multiple countries of different levels 1 (4%)
Type of setting
Health care 20 (80%)
Non-health care 5 (20%)
Type of clusters
General practice 3 (12%)
Hospital/ward/specialities 9 (36%)
Nursing homes 2 (8%)
Other cluster in health setting 3 (12%)
Geographical unit 5 (20%)
Other/unclear 3 (12%)
Number of sequences
3 5 (20%)
4 6 (24%)
5 2 (8%)
6 or more 11 (44%)
Unclear 1 (4%)
Median (IQR) 5 (4e8)
Number of clusters
3 1(4%)
4 4 (16%)
5e10 5 (20%)
11e15 5 (20%)
O15 10 (40%)
Median (IQR) 13 (6e20)
Abbreviations: IQR, interquartile range.
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to be reserve reviewers. Of the remaining 50 participants,
four dropped out (one dropped out before the day, one
was a duplicate registration, and two did not attend on
the day). One participant on the waiting list to attend the
workshop was invited to attend to replace the participant
who dropped out before the event.The three participants invited to act as reserves all at-
tended the event and each acted as a replacement for the
three participants who did not attend the workshop (two
of these provided an independent assessment for their sub-
sequently allocated article, one of which was done un-
blinded to the other reviewers assessment). At the end of
the event, 47 independent assessments were provided, some
of which included missing items (two of the invited partic-
ipants did not return their independent assessment at the
end of the workshop), and we received 25 completed joint
assessments on 25 trials.
The participants were mainly from the UK (84%); the
majority worked in University settings (72%); and most
were statisticians, although a number were clinicians
(18%) spanning a range of career levels; with most having
being involved some way in a stepped-wedge trial and a
small number having participated in development of CON-
SORT statements (Supplementary Table S1).3.3. Reliability of quality assessments
Some items showed very high agreement (observer per-
centage agreement) across the independent assessments,
within items, and across reviewer pairs (Table 2;
Supplementary Fig. S1). For example, reviewers were in
agreement 100% of the time as to whether the title was
clearly reported (item 1a). Reviewers were also very often
in agreement for the reporting of item 5 (interventions),
item 10c (consent), item 23 (trial registration), item 24
(protocol), and item 26 (funding). Some items showed
particularly poor agreement across independent assess-
ments. These included item 3a (trial design), item 8b (type
of randomization), item 11b (if relevant, description of the
similarity of the treatments), item 13a (flow diagram), item
14b (why the trial ended), and item 22 (interpretation) all in
agreement less than 60% of the time. Over all 26 items, the
median percentage agreement was 53% (IQR: 43e64) and
the median Gwet’s A1 statistic was 0.41 (IQR 0.29e0.55)
when comparing agreement across the four possible assess-
ment categories. Median agreement increased to 76% (IQR:
67e86) when the comparison was made across a two-point
scale. The median Gwet’s A1 statistic across all items on
the two-point score was 0.72 (IQR: 0.59e0.90). As ex-
pected, reliability was higher on the two-point scale
compared with the four-point scale.3.4. Quality of reporting of SW CONSORT items in the
25 trial reports based on the joint assessment of
reviewers
There was variability among trial reports in the quality
of reporting (Table 3; Supplementary Fig. S2), with the me-
dian number of items reported (clearly or partially) was 28
(IQR: 23 to 30) of a total of 40 separate items. Several
items were assessed as being well reported in the joint
assessment. These included item 1b (structured summary),
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Fig. 2. Flow diagram of participants carrying out the review.
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tions where data were collected), item 5 (description of
intervention and control conditions), item 6a (outcomes),
item 15 (baseline table), item 17a (results), item 25 (sources
of funding and other support, role of funder), and item 26
(whether the study was approved by a research ethics com-
mittee); all clearly reported more than 80% of the time.
Other items were poorly reported. In particular, the
following items were clearly reported less than 50% of
the time (in order of appearance in the statement): item
2a (rationale and justification for the trial design), item 3a
(description of trial design), item 3b (important changes
to methods after trial commencement), item 6b (any
changes to trial outcomes after the trial commenced), item
11a (blinding), item 19 (important harms), item 21 (gener-
alizability), and item 24 (where the full trial protocol can be
accessed, if available). All items involving randomization
were also poorly reported. This included item 8a (methods
used to generate the random allocation), item 8b (type of
randomization), item 9 (specification that allocation wasbased on the clusters; description of any methods used to
conceal the allocation from the clusters until after recruit-
ment), item 10a (who generated the randomization), and
item 10b (mechanism by which individual participants
were included in the trial [such as complete enumeration,
random sampling]).3.5. Quality of reporting for each article and reliability
within pairs of reviewers
Making comparisons within reviewer pairs and across
items, the percentage agreement (on a two-point scale) across
all items ranged between 38% (reviewer pair 9) and 83%
(reviewer pair 22). The median Gwet’s A1 statistic across all
pairs was 0.42 (IQR: 0.36e0.51) (Supplementary Table S2).
The median number of items (out of the total of 40 subitems)
assessed as being clearly reported was similar between the in-
dependent assessments (median [IQR]) is 26 ([IQR 21e29]
not shown in tables) and 28 (IQR 23e30) for the joint assess-
ments as previously mentioned.
Table 2. Percentage agreement for each item across reviewer pairs
Item N (reviewers)
Four-point scale Two-point scale
Agreement Gwet’s A1 statistic (95% CI) Agreement Gwet’s Al statistic (95% CI)
Title and abstract
Item 1a 44 82% 0.78 (0.52: 1.00) 100% 1.00 (0.84: 1.00)
Item 1b 44 55% 0.43 (0.13: 0.73) 86% 0.81 (0.54: 1.00)
Background and objectives
Item 2a 44 41% 0.25 (0.05: 0.55) 73% 0.49 (0.08: 0.91)
Item 2b 42 52% 0.41 (0.09: 0.73) 81% 0.68 (0.33: 1.00)
Design
Item 3a 44 45% 0.29 (0.00: 0.59) 59% 0.23 (0.23: 0.68)
Item 3b 34 65% 0.56 (0.22: 0.91) 76% 0.55 (0.10: 1.00)
Participants
Item 4a 44 50% 0.35 (0.05: 0.65) 64% 0.39 (0.05: 0.83)
Item 4b 42 43% 0.30 (0.01: 0.60) 76% 0.64 (0.27: 1.00)
Interventions
Item 5 44 59% 0.49 (0.20: 0.77) 95% 0.94 (0.75: 1.00)
Outcomes
Item 6a 42 43% 0.29 (0.02: 0.60) 76% 0.69 (0.36: 1.00)
Item 6b 32 69% 0.64 (0.29: 0.99) 75% 0.61 (0.16: 1.00)
Sample size
Item 7a 42 52% 0.37 (0.06: 0.68) 71% 0.44 (0.01: 0.86)
Item 7b 16 75% 0.72 (0.17: 1.00) 75% 0.69 (0.12: 1.00)
Randomization
Item 8a 44 68% 0.60 (0.31: 0.88) 82% 0.66 (0.30: 1.00)
Item 8b 42 43% 0.26 (0.04: 0.57) 57% 0.16 (0.31: 0.63)
Allocation
Item 9 44 59% 0.46 (0.16: 0.76) 86% 0.73 (0.40: 1.00)
Implementation
Item 10a 44 59% 0.51 (0.21: 0.81) 82% 0.75 (0.45: 1.00)
Item 10b 42 43% 0.24 (0.07: 0.55) 67% 0.35 (0.10: 0.80)
Item 10c 42 52% 0.38 (0.06: 0.69) 90% 0.82 (0.52: 1.00)
Blinding
Item 11a 30 60% 0.51 (0.12: 0.89) 80% 0.69 (0.26: 1.00)
Item 11b 18 56% 0.44 (0.05: 0.93) 56% 0.21 (0.45: 0.88)
Statistical analysis
Item 12a 44 55% 0.41 (0.11: 0.72) 77% 0.63 (0.27: 0.99)
Item 12b 40 50% 0.37 (0.04: 0.70) 85% 0.74 (0.39: 1.00)
Flow diagram
Item 13a 44 27% 0.05 (0.22: 0.31) 59% 0.26 (0.21: 0.72)
Item 13b 42 29% 0.06 (0.21: 0.33) 71% 0.47 (0.05: 0.89)
Recruitment
Item 14a 44 50% 0.34 (0.04: 0.64) 86% 0.73 (0.40: 1.00)
Item 14b 28 36% 0.19 (0.16: 0.55) 50% 0.02 (0.55: 0.58)
Baseline data
Item 15 44 64% 0.54 (0.25: 0.83) 86% 0.81 (0.53: 1.00)
Numbers analyzed
Item 16 42 19% 0.08 (0.31: 0.16) 62% 0.26 (0.21: 0.72)
Outcomes and estimation
Item 17a 42 57% 0.45 (0.14: 0.75) 71% 0.55 (0.15: 0.95)
Item 17b 30 40% 0.22 (0.14: 0.59) 67% 0.34 (0.17: 0.86)
(Continued )
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Table 2. Continued
Item N (reviewers)
Four-point scale Two-point scale
Agreement Gwet’s A1 statistic (95% CI) Agreement Gwet’s Al statistic (95% CI)
Auxiliary analysis
Item 18 38 47% 0.30 (0.02: 0.63) 68% 0.38 (0.09: 0.85)
Harms
Item 19 34 71% 0.66 (0.32: 1.00) 88% 0.82 (0.48: 1.00)
Limitations
Item 20 40 45% 0.29 (0.02: 0.59) 75% 0.57 (0.18: 0.96)
Generalizability
Item 21 36 56% 0.41 (0.06: 0.75) 67% 0.34 (0.13: 0.82)
Interpretation
Item 22 40 40% 0.25 (0.06: 0.56) 60% 0.37 (0.09: 0.83)
Registration
Item 23 42 81% 0.77 (0.51: 1.00) 90% 0.82 (0.51: 1.00)
Protocol
Item 24 38 79% 0.74 (0.44: 1.00) 95% 0.91 (0.63: 1.00)
Funding
Item 25 42 76% 0.73 (0.46: 1.00) 90% 0.88 (0.63: 1.00)
Research ethics
Item 26 42 71% 0.62 (0.31: 0.93) 76% 0.59 (0.20: 0.98)
All items (median IQR) 53% (43%, 64%) 0.41 (0.29, 0.55) 76% (67%, 86%) 0.62 (0.38, 0.74)
Abbreviations: IQR, interquartile range; CI, confidence interval; N, number of reviewers.
Four-point scale classifies each item as: clearly and fully reported/clearly but partially recorded/unclearly reported/not reported.
Two-point scale classified each item as: clearly and fully reported or partially recorded/unclearly or not reported.
Any ‘‘not applicable’’ are excluded.
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4.1. Principal findings
We have reported, using an innovative review approach
capitalizing on the interests and expertise of delegates at a
workshop, an assessment of quality of reporting of SW-
CRTs according to the new extension of the CONSORT
statement for this trial design. Perhaps unsurprisingly we
have identified suboptimal reporting. Items particularly
poorly reported were those items detailing the justification
and design of the study and information on the method of
randomization, including the method of recruitment and
allocation of clusters and participants. Some items with
low reporting are specific to the SW-CRT (such as justifica-
tion of the design); others are not specific and include such
things as identification of the trial protocol. Two items, item
11b (description of the similarity of the treatments) and
item 14b (why the trial ended or stopped) might not be rele-
vant to many SW-CRTs despite their inclusion in the up-
dated statement.4.2. Implications
Clear reporting of who recruited or identified partici-
pants and whether or not such individuals were blind to
allocation is important so readers can determine the risks
for recruitment and selection biases [20,17]. We identifiedthat a description of any methods used to conceal the allo-
cation from the clusters until after recruitment was poorly
reported, as was the mechanism by which individual partic-
ipants were included in clusters for the purposes of the trial
(such as complete enumeration or random sampling;
continuous recruitment or ascertainment, or recruitment at
a fixed point in time), including who recruited or identified
participants [9,7]. In parallel cluster trials, it has recently
been proposed that trials should report a timeline diagram
to allow clear identification of the timing of randomization
with respect to recruitment of clusters and participants [20].
Whether such a diagram could be modified for the SW-CRT
remains to be investigated.
We also identified suboptimal reporting of the format of
the design and justification for use of the SW-CRT. Clear
reporting of the exact form of the design is necessary to
determine whether the appropriate sample size and analysis
methods have been used [13]. Clear reporting of the justifi-
cation for use of the design is important to determine if the
study is ethically appropriate [11].
Although some basic items were well reported, such as
the title, sources of funding, and ethics review, a substantial
minority of reports failed to report these essential details
and many failed to report where the full trial protocol can
be assessed. We identified that 32% of this very recent sam-
ple of SW-CRTs did not report trial registration clearly.
Trial registration is known to increase transparency of
Table 3. Joint assessment of the quality of reporting for 26 items of CONSORT extension for the SW-CRT
Item Detailed description
Clearly reporteda
Reported/N (%)
Item 1a Identification as a stepped-wedge cluster randomized trial in the title. 15/25 (60%)
Item 1b Structured summary of trial design, methods, results, and conclusions. 20/25 (80%)
Item 2a Scientific background. Rationale for using a cluster design and rationale for using a stepped-wedge design 10/25 (40%)
Item 2b Specific objectives or hypotheses 17/25 (68%)
Item 3a Description and diagram of trial design including definition of cluster, number of sequences, number of
clusters randomized to each sequence, number of periods, duration of time between each step, and
whether the participants assessed in different periods are the same people, different people, or a mixture
13/24 (54%)
Item 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons. 12/25 (48%)
Item 4a Eligibility criteria for clusters and participants. 21/25 (84%)
Item 4b Settings and locations where the data were collected. 21/23 (91%)
Item 5 The intervention and control conditionswith sufficient details to allow replication, including howandwhen they
were administered; whether the intervention was delivered at the level of the cluster, the individual, or both.
21/25 (84%)
Item 6a Completely defined prespecified primary and secondary outcome measures, including how and when they
were assessed.
20/25 (80%)
Item 6b Any changes to trial outcomes after the trial commenced, with reasons 10/25 (40%)
Item 7a How sample size was determined. Method of calculation and relevant parameters with sufficient detail so the
calculation can be replicated. Assumptions made about correlations between outcomes of participants from the
same cluster.
14/25 (56%)
Item 7b When applicable, explanation of any interim analyses and stopping guidelines. 15/25 (60%)
Item 8a Method used to generate the random allocation to the sequences of treatments. 10/24 (42%)
Item 8b Type of randomization; details of any constrained randomization or stratification if used. 12/25 (48%)
Item 9 Specification that allocation was based on clusters; description of any methods used to conceal the
allocation from the clusters until after recruitment.
10/25 (40%)
Item 10a Who generated the randomization schedule, who enrolled clusters, and who assigned clusters to sequences 5/25 (20%)
Item 10b Mechanism by which individual participants were included in clusters for the purposes of the trial (such as
complete enumeration, random sampling; continuous recruitment/ascertainment, or recruitment at a fixed
point in time), including who recruited or identified participants.
11/25 (44%)
Item 10c Whether, from whom and when consent was sought and for what; whether this differed between treatment
conditions.
14/25 (56%)
Item 11a If done, who was blinded after assignment to sequences (e.g., cluster level participants, individual level
participants, those assessing outcomes) and how.
7/25 (28%)
Item 11b If relevant, description of the similarity of treatments. 16/24 (67%)
Item 12a Statistical methods used to compare treatment conditions for primary and secondary outcomes including
how time effects, clustering, and repeated measures were taken into account.
17/25 (68%)
Item 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses. 17/25 (68%)
Item 13a For each treatment condition or allocated sequence, the numbers of clusters and participants whowere assessed for
eligibility were randomly assigned, received intended treatments, and were analyzed for the primary outcome.
16/25 (64%)
Item 13b For each treatment condition or allocated sequence, losses and exclusions for both clusters and participants
with reasons.
14/25 (56%)
Item 14a Dates defining the steps, initiation of intervention, and deviations from planned dates. Dates defining
recruitment and follow-up for participants.
14/25 (56%)
Item 14b Why the trial ended or was stopped 17/25 (68%)
Item 15 Baseline characteristics for the individual and cluster levels as applicable for each treatment condition or
allocated sequence.
22/25 (88%)
Item 16 The number of observations and clusters included in each analysis for each treatment condition and whether
the analysis was according to the allocated schedule.
16/25 (64%)
Item 17a For each primary and secondary outcome, results for each treatment condition, and the estimated effect size and
its precision (such as 95% confidence interval); any correlations and time effects estimated in the analysis.
21/25 (84%)
Item 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended. 18/25 (72%)
Item 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing
prespecified from exploratory.
16/24 (67%)
(Continued )
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Table 3. Continued
Item Detailed description
Clearly reporteda
Reported/N (%)
Item 19 Important harms or unintended effects in each treatment condition (for specific guidance seeCONSORT for harms). 9/25 (36%)
Item 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses. 16/24 (67%)
Item 21 Generalizability (external validity, applicability) of the trial findings. Generalizability to clusters and/or
individual participants (as relevant).
11/24 (46%)
Item 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant
evidence.
19/24 (79%)
Item 23 Registration number and name of trial registry. 17/25 (68%)
Item 24 Where the full trial protocol can be accessed, if available. 7/25 (28%)
Item 25 Sources of funding and other support (such as supply of drugs), role of funders. 23/24 (96%)
Item 26 Whether the study was approved by a research ethics committee, with identification of the review
committee(s). Justification for any waiver or modification of informed consent requirements.
20/25 (80%)
All Total (out of 40) number of items clearly or fully reported (median [IQR]) 28 (23e30)
a Includes not applicable.
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tive reporting [21-23]. Related to this, an earlier in-depth
review of the quality of reporting of the ethical conduct
and reporting of SW-CRTs identified poor reporting and
identification of the research participant, informed consent,
and ethical review [19]. In light of this, when the CON-
SORT extension for the SW-CRT was developed, it intro-
duced an extra item to encourage transparent reporting of
ethical review. This review echoes previous findings and
highlights how a significant minority of SW-CRTs fail to
report any ethical review processes or provide details of
the trial protocol, despite these being endorsed by the Inter-
national Committee of Medical Journal Editors [24]. These
findings might indicate a misconception that SW-CRTs are
different to conventional trials and do not need to be re-
ported or conducted with similar standards.4.3. What is already known
The CONSORT statement describes a minimum set of
items that should be reported in any clinical trial to ensure
transparent reporting. Without transparent reporting, the
validity of the methods and the results cannot be assessed
and this can have wide ranging medical implications [25].
Studies published in endorsing journals are more likely to
report this minimum set of items than those that do not
[26]; and reviews have suggested an increase in quality of
reporting post publication of reporting guidelines [27,28].
There have been several reviews of the quality of reporting
of SW-CRTs. Early reviews however did not assess quality of
reporting against the CONSORT items [29]; other reviews,
while assessing reporting against the CONSORT extension
for cluster randomized trials, gave in-depth reviews, for
example, assessing quality of reporting of sample size [2]
or analysis items only [16]. Reviews assessing quality of re-
porting against all of the items in the CONSORT extensionfor cluster trials have demonstrated, not surprisingly, subop-
timal reporting [18]. This suboptimality might have been ex-
plained partly by the necessary inclusion of older trials (to
avoid an overly small sample size) and the lack of relevance
or coherence of items written with an individually random-
ized or parallel cluster trial in mind.4.4. Strengths and limitations
This methodological review used a novel approach to
data abstraction, capitalizing on the interest and willingness
of a group of methodologists, attending a small conference
to undertake quality assessments. The number of articles re-
viewed was small (25) but represents a substantial propor-
tion of the total number of stepped-wedge trials
undertaken to date (40 completed trial reports up to February
2015) [18]. Furthermore, the date range was selected to be
mutually exclusive with other recent methodological reviews
[18,2]. Being the most recent year at the time of the review,
our results reflect current reporting practices. There was
some variation across reviewers in degrees of expertise
and knowledge of the design, but all participants were given
a short briefing via the introductory presentation. Reports
were randomly allocated to the reviewers, and data were
abstracted independently to the other reviewers and then in
duplicate. One important limitation is that participants were
asked to assess quality of reporting on a four-point scale for
their independent assessment; this was changed to a five-
point scale by adding the category ‘‘not applicable’’ for
the joint assessment. On the four-point scale, agreement
was low; when agreement was considered on a two-point
scale, (i.e., reported partially or fully vs. not reported or un-
clearly reported) agreement improved. However, even on
this two-point scale, agreement was poor for some items.
Items with low agreement might be less clearly worded in
the trial reports than items with higher agreement.
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items with unclear wording, some of our results might be
suggestive of items with insufficient wording clarity. Any
future revisions of the CONSORT statement for SW-
CRTs might pay particular attention therefore to the
wording and relevance of items 11b (if relevant, description
of the similarity of treatments) and 14b (why the trial ended
or was stopped). Any robust attempt to study the clarity of
the wording of CONSORT items would ideally be pre-
planned and include a range of diverse stakeholders (tria-
lists, principal investigators, clinicians etc.) and likely
include a qualitative assessment as well as a quantitative
assessment of agreement.
We also observed variability in agreements within pairs,
with some pairs of reviewers consistently agreeing across
items and other pairs of reviewers mostly disagreeing
across items. Agreement may have been improved with
additional training of assessors (there was no association
between quality of the study report as assessed by the joint
assessment and level of agreement of independent asses-
smentseTable S2).5. Conclusions
The CONSORT extension for SW-CRTs provides spe-
cific and tailored guidance for the reporting of SW-CRTs.
Clear reporting is crucial to allow assessment of the risks
of bias and transparent interpretation of the results of
studies. Although this review echoes the findings of
many other assessments of reporting reviews, that report-
ing needs to be improved, we provide clear guidance of
items, which require particular attention as they are
frequently poorly reported. Of note, researchers should
pay careful attention to the reporting of how clusters
and participants are recruited or sampled; and whether
this was done without knowledge of the randomized allo-
cation. Exactly how the design, results, and interpreta-
tion of an SW-CRT should be reported is different to
that of individually randomized and parallel cluster tri-
als. Any future updates of the CONSORT extension for
SW-CRTs should pay careful attention to the wording
and relevance of items with low agreement between re-
viewers, including why the trial stopped, which may
not be relevant to many SW-CRTs. Future developments
of guidelines for reporting might assess reliability before
publication and as a final stage in the development of the
reporting guideline.Acknowledgments
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